XTLB XTL BIOPHARMACEUTICALS LTD IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1023549
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2022Q2*2022-06-30 | 2021Q2*2021-06-30 | 2020Q2*2020-06-30 |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | — |
| R&D expense | $15,000 | $6,000 | $11,000 |
| SG&A expense | $187,000 | $297,000 | $206,000 |
| Operating income | -$202,000 | -$303,000 | -$217,000 |
| Net income | -$285,000 | -$1.15M | -$1.10M |
| EPS (basic) | -0.00 | -0.00 | — |
| EPS (diluted) | -0.00 | -0.00 | — |
| Weighted avg. shares (diluted) | 544.91M | 527.79M | — |
| Balance sheet | |||
| Cash & equivalents | $2.35M | $2.92M | $4.03M |
| Short-term investments | $2.81M | $3.38M | — |
| Current assets | $5.38M | $6.57M | — |
| Intangibles | $380,000 | $380,000 | — |
| Total assets | $5.76M | $6.95M | — |
| Total liabilities | $194,000 | $3.67M | — |
| Shareholders' equity | $5.56M | $3.28M | $5.59M |
| Shares outstanding | 544.91M | 528.16M | — |
| Cash flow statement | |||
| Operating cash flow | — | — | — |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.